Navigation Links
EU5 Nephrologists Report a Decreasing Trend in the Treatment Prevalence of ESAs in the Haemodialysis Patient Population
Date:2/7/2013

EXTON, Pa., Feb. 7, 2013 /PRNewswire/-- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the following key results, according to a recent BioTrends' study, ChartTrends: Renal Anaemia in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis, of 962 EU5 dialysis patient charts and 928 EU5 CKD-ND patient charts:

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

  • Erythropoiesis-stimulating agents (ESAs) treatment prevalence in both haemodialysis (HD) and peritoneal dialysis (PD) patient populations has declined from two years ago and the decline of 9 percent in HD reached statistical significance
  • Surveyed nephrologists significantly over-estimate the haemoglobin level at which they initiate ESAs in dialysis; this finding is pronounced in every EU5 country with the exception of Italy
  • ESA treatment prevalence in the Stage 4 CKD-ND patient population is up 12 percent from two years ago, according to 382 Stage 4 CKD-ND patient charts
  • Nephrologists significantly underestimate their use of ESAs in Stage 4 (predominately in France and Italy) and directionally in Stage 5 non-dialysis (significantly in Italy)
  • Aranesp (Amgen), Eprex/Erypo (Janssen-Cilag), NeoRecormon (Roche) and Mircera (Roche) and collectively ESA biosimilars are leading the dialysis market. In particular, ESA biosimilars in the dialysis population have reached mid-teen double-digit patient share, but use is much less in the CKD-ND patient population
  • HD IV iron treatment prevalence has remained flat from two years ago, but nephrologists over-estimate the use of IV iron in PD and under-estimate the use of oral iron in PD 
  • In CKD-ND, Venofer (Vifor Pharmaceuticals), Ferinject (Vifor Pharmaceuticals) and Ferrlecit (Sanofi) lead this space. Rienso, which recently launched in EU5 from Takeda Pharmaceuticals (developed by AMAG Pharmaceuticals), has captured minimal share at this point
  • "ESA cardiovascular warnings and cost containment pressures may be the reason for these declining ESA treatment prevalences found in the dialysis patient charts," said Rob Dubman , BioTrends' Director of Nephrology.

    ChartTrends: Renal Anaemia in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis is a syndicated report series, in which 210 nephrologists provided patient chart data on 962 dialysis patients in the EU5 and 191 nephrologists provided patient chart data on 928 CKD-ND patients in the EU5 in the most recent wave of research to uncover the actual management related to renal anaemia. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.

    The study also evaluated referral patterns, co-morbidities, blood transfusions, hospitalizations and a host of other patient demographics and laboratory data. BioTrends is publishing ChartTrends: Renal Anemia in dialysis and CKD-ND reports later this year in the US. Additional ChartTrends Dialysis reports have been published in China and Latin America (Brazil, Argentina and Mexico).

    About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. About Decision Resources Group
    Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.All company, brand, or product names contained in this document may be trademarks of their respective holders.

     For more information, contact: BioTrends Research Group, LLC  Decision Resources GroupRob Dubman

     Christopher Comfort781-993-2592

     781-993-2597 rdubman@bio-trends.com  ccomfort@dresources.com


    '/>"/>
    SOURCE BioTrends Research Group
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations
    2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
    4. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
    5. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    6. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    8. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    9. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    11. Chindex International, Inc. to Report First Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
    (Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
    (Date:9/13/2017)... ATLANTA , Sept. 13, 2017   OrthoAtlanta ... to the Atlanta Football Host Committee (AFHC) for the 2018 ... Monday, Jan. 8, 2018, at Mercedes-Benz Stadium in ... part of the AFHC "I,m In" campaign, participating in many ... ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
    (Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
    (Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
    (Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
    (Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
    Breaking Medicine News(10 mins):